A Phase II of Anti IL-17 A/F Nanobody for plaque psoriasis

Trial Profile

A Phase II of Anti IL-17 A/F Nanobody for plaque psoriasis

Planning
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2017

At a glance

  • Drugs ALX 0761 (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Apr 2017 New trial record
    • 30 Mar 2017 According to a Merck AG media release, this trial is expected to begin in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top